Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol
Authors:
- 6 November 2006
- journal article
- case report
- Published by Wiley in Haemophilia
- Vol. 12 (6) , 663-667
Abstract
Summary. Inhibitors are an uncommon complication of mild haemophilia A but represent a severe disease, typically with high titre inhibitors and an associated high rate of bleeding. We present data from three patients with MHAI who were successfully treated with Rituximab alone and unequivocally prove that such inhibitors respond to this agent. A treatment protocol is suggested.Keywords
This publication has 18 references indexed in Scilit:
- The use of rituximab in two children with allo-antibodies towards factor VIIIBritish Journal of Haematology, 2006
- Impact of Choice of Treatment for Bleeding Episodes on Inhibitor Outcome in Patients With Mild/Moderate Hemophilia A and InhibitorsSeminars in Hematology, 2006
- High-dose factor VIII inhibits factor VIII–specific memory B cells in hemophilia A with factor VIII inhibitorsBlood, 2005
- Inhibitors in congenital coagulation disordersBritish Journal of Haematology, 2004
- Inhibitors in haemophilia: pathophysiologyHaemophilia, 2004
- The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99Journal of Thrombosis and Haemostasis, 2004
- Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophiliaBlood, 2004
- Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophiliaBritish Journal of Haematology, 2004
- Rituximab therapy for multisystem autoimmune diseases in pediatric patientsThe Journal of Pediatrics, 2003
- Rituximab in the treatment of acquired factor VIII inhibitorsBlood, 2002